万泰生物：全资子公司参与国家免疫规划疫苗集中采购项目入围

Group 1 - The company, Wantai Biological Pharmacy, announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., participated in the bidding for the 2025 National Immunization Program vaccine centralized procurement project for the bivalent human papillomavirus vaccine [2] - The company's bivalent human papillomavirus vaccine (E. coli) has been shortlisted, with a unit price of RMB 27.5 [2]